Aktie A2JRNR NEUROSCIENTIFIC BIOPHARMACEUTICALS LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen NeuroScientific Biopharmaceuticals Limited

Aktien

A2JRNR

AU0000012973

NSB

Markt geschlossen - Australian S.E.
Andere Börsenplätze
 07:40:16 28.06.2024 		% 5 Tage % 1. Jan.
0.04 AUD +2.56% Intraday Chart für NeuroScientific Biopharmaceuticals Limited +2.56% -9.09%
11.06. Neuroscientific Biopharmaceuticals sichert sich US FDA Guidance für Glaukom-Medikament MT
20.03. NeuroScientific Biopharmaceuticals sichert sich AU$2 Millionen F&E-Steuernachlass für das Geschäftsjahr 2023; Aktien steigen um 6% MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Neuroscientific Biopharmaceuticals Secures US FDA Guidance for Glaucoma Medication
NeuroScientific Biopharmaceuticals Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 6%
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023
NeuroScientific Biopharmaceuticals Limited Announces Changes to Board of Directors
NeuroScientific Biopharmaceuticals CEO to Step Down
NeuroScientific Biopharmaceuticals Limited Announces Resignation of Stephen Carter as CEO Effective 31 December 2023
Linda Friedland Steps Down from the Board of NeuroScientific Biopharmaceuticals Limited, Effective 17 November 2023
Neuroscientific Biopharmaceuticals Limited Announces Board Changes
NeuroScientific Biopharmaceuticals Ltd Appoints Linda Friedland as Independent Non-Executive Director
Neuroscientific Biopharmaceuticals Limited Announces Chief Executive Officer Changes
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023
Neuroscientific Biopharmaceuticals Announce Positive Treatment Effect in Multiple sclerosis Animal Study
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022
Neuroscientific Biopharmaceuticals Files New Patent for Multiple Sclerosis Treatment; Shares Jump 7%
NeuroScientific Biopharmaceuticals Files A New Patent, Entitled "Neuroprotective Compositions and Methods"
NeuroScientific Biopharmaceuticals Names Interim CEO; Shares Climb 12%
NeuroScientific Biopharmaceuticals Limited Announces Appointment of Mr. Paul Rennie as Interim CEO
NeuroScientific Biopharmaceuticals Limited Announces Management Changes
NeuroScientific Biopharmaceuticals Ltd Announces Resignation of Matt Liddelow as Managing Director
NeuroScientific Biopharmaceuticals Ltd Announces Resignation of Matt Liddelow as CEO
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2JRNR Aktie
  4. Nachrichten NeuroScientific Biopharmaceuticals Limited
  5. Andere Sprachen